查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951807

下一代疫苗技术市场分析及预测（至2035年）：按类型、产品类型、技术、应用、最终用户、组件、设备、製程、部署类型和解决方案划分

Next-Generation Vaccination Technologies Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Component, Device, Process, Deployment, Solutions
出版日期: | 出版商: Global Insight Services | 英文 307 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计下一代疫苗技术市场将从2024年的342亿美元成长到2034年的2,028亿美元，复合年增长率约为23.7%。该市场涵盖了疫苗研发和给药的先进方法，包括mRNA平台、病毒载体和奈米颗粒系统。这些创新技术旨在提高疫苗的有效性、安全性和生产速度。对快速应对新兴感染疾病、个人化疫苗接种策略以及提高全球疫苗可及性的需求不断增长，正在推动市场成长。关键趋势包括佐剂、热稳定性以及无针给药系统等方面的技术进步，这些进步有助于克服疫苗分发和给药方面的挑战。

下一代疫苗技术市场预计将迎来显着成长，这主要得益于生物技术创新和全球健康意识的不断提高。 mRNA疫苗凭藉其快速的研发能力和对多种病原体的适应性，在性能方面占据主导地位。 DNA疫苗紧随其后，这主要归功于其稳定性和易于生产的优势。佐剂技术在疫苗递送系统领域中日益受到重视，因为它能够增强疫苗的效力和免疫抗原性。病毒载体疫苗也备受关注，尤其是诱发强效免疫反应的能力。基于奈米颗粒的递送系统正成为实现标靶和可控疫苗递送的一个极具前景的领域。低温运输物流和储存解决方案的创新正在确保疫苗的效力和供应，从而进一步推动市场扩张。人工智慧驱动的分析和数据管理平台等数位健康技术的整合正在优化疫苗的分发和监测，为相关人员带来盈利的机会。

市场区隔
按类型 重组疫苗、DNA疫苗、RNA疫苗、次单位疫苗、载体疫苗、减毒活病毒疫苗、去活化疫苗、合成疫苗
产品 疫苗製剂、佐剂、疫苗接种装置、疫苗包装、疫苗储存方案
科技 奈米颗粒技术、类病毒颗粒、偶联技术、基因编辑、合成生物学、反向疫苗学
应用领域 感染疾病、癌症疫苗、过敏疫苗、自体免疫疾病、神经系统疾病
最终用户 医院、诊所、研究机构、生物製药公司、政府机构
成分 抗原、稳定剂、防腐剂、佐剂
装置 无针注射器、微针贴片、口服给药系统、吸入装置
过程 发酵、细胞培养、纯化、配方
实施表格 本机部署、云端部署、混合式部署
解决方案 低温运输管理、疫苗追踪系统

下一代疫苗技术市场的特点是市场份额波动剧烈，各公司透过策略定价和创新产品推出争夺主导。竞争格局的特点是新参与企业数量迅速增长，每个新进入者都提供尖端解决方案，承诺提高疫苗的有效性和安全性。现有企业正利用其市场地位推出先进疫苗，以满足日益增长的有效疫苗需求。应对新兴感染疾病的需求进一步加剧了这种竞争格局，推动了持续的创新和适应。在竞争基准评估方面，领先的製药公司主要根据其技术进步和策略联盟进行评估。监管影响至关重要，北美和欧洲的严格指导方针对市场准入和扩张起着决定性作用。在基因研究和生物技术进步的推动下，市场正朝着个人化疫苗解决方案发展。人工智慧和数据分析的整合正在提升疫苗研发流程，使企业处于技术创新的前沿。对于愿意应对监管复杂性并投资于研发的利害关係人相关人员，这种格局蕴藏着盈利机会。

主要趋势和驱动因素：

下一代疫苗技术市场正经历强劲成长，这主要得益于生物技术的进步以及研发投入的不断增加。关键趋势包括mRNA疫苗的研发，由于其研发速度快、疗效高，正日益受到关注。根据个体基因谱量身定制的个人化疫苗也正在蓬勃发展，提供更有效的免疫策略。另一个重要趋势是将人工智慧（AI）和机器学习应用于疫苗研发，从而加速筛选出有前景的候选疫苗。推动市场成长的因素包括应对疫情的迫切性以及全球对更有效率、扩充性的疫苗生产方法的需求。感染疾病的日益普及以及对创新疫苗解决方案的需求进一步推动了市场成长。新兴市场蕴藏着许多机会，政府主导的措施和国际合作正在扩大疫苗接种覆盖范围。投资下一代平台和技术的公司将能够更好地掌握这些新机会。此外，着力改善疫苗分发和储存，尤其是在偏远地区，也为市场开闢了新的成长途径。随着世界各国继续将健康安全放在首位，下一代疫苗技术市场预计将持续扩张。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 重组疫苗
    • DNA疫苗
    • RNA疫苗
    • 次单位疫苗
    • 基于载体的疫苗
    • 减毒活病毒疫苗
    • 灭活疫苗
    • 合成疫苗
  • 市场规模及预测：依产品划分
    • 疫苗製剂
    • 佐剂
    • 疫苗输送装置
    • 疫苗包装
    • 疫苗储存方案
  • 市场规模及预测：依技术划分
    • 奈米颗粒技术
    • 类病毒颗粒
    • 组合技术
    • 基因编辑
    • 合成生物学
    • 反向疫苗学
  • 市场规模及预测：依应用领域划分
    • 感染疾病
    • 癌症疫苗
    • 过敏疫苗
    • 自体免疫疾病
    • 神经系统疾病
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊所
    • 研究所
    • 生物製药公司
    • 政府机构
  • 市场规模及预测：依组件划分
    • 抗原
    • 稳定器
    • 防腐剂
    • 佐剂
  • 市场规模及预测：依设备划分
    • 无针注射器
    • 微针贴片
    • 口服给药系统
    • 吸入装置
  • 市场规模及预测：依製程划分
    • 发酵
    • 细胞培养
    • 纯化
    • 配方
  • 市场规模及预测：依发展状况
    • 本地部署
    • 基于云端的
    • 杂交种
  • 市场规模及预测：按解决方案划分
    • 低温运输管理
    • 疫苗追踪系统

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Cure Vac
  • Valneva
  • Novavax
  • Inovio Pharmaceuticals
  • Vaxart
  • Geo Vax Labs
  • Moderna
  • Bio NTech
  • Dynavax Technologies
  • Bavarian Nordic
  • Arcturus Therapeutics
  • Immunomic Therapeutics
  • Medicago
  • Altimmune
  • Emergent Bio Solutions
  • Gritstone Oncology
  • Sorrento Therapeutics
  • Translate Bio
  • Vir Biotechnology
  • Icosavax

第九章：关于我们

简介目录
Product Code: GIS32951

Next-Generation Vaccination Technologies Market is anticipated to expand from $34.2 billion in 2024 to $202.8 billion by 2034, growing at a CAGR of approximately 23.7%. The Next-Generation Vaccination Technologies Market encompasses advanced methods for vaccine development and delivery, including mRNA platforms, viral vectors, and nanoparticle-based systems. These innovations aim to enhance efficacy, safety, and production speed. The market is propelled by increasing demand for rapid response to emerging infectious diseases, personalized immunization strategies, and improved global vaccine access. Key trends include technological advancements in adjuvants, thermostability, and needle-free delivery systems, addressing challenges in distribution and administration.

The Next-Generation Vaccination Technologies Market is poised for substantial growth, driven by advancements in biotechnological innovations and increasing global health awareness. The mRNA vaccine segment leads in performance, attributed to its rapid development capabilities and adaptability to various pathogens. DNA vaccines follow as the second highest performing segment, benefiting from their stability and ease of production. The adjuvant technologies sub-segment within the delivery systems segment is gaining prominence, enhancing vaccine efficacy and immunogenicity. Viral vector vaccines are also experiencing significant traction, particularly for their ability to elicit strong immune responses. Nanoparticle-based delivery systems are emerging as a promising area, offering targeted and controlled vaccine delivery. Innovations in cold chain logistics and storage solutions further support the market's expansion, ensuring vaccine potency and accessibility. The integration of digital health technologies, such as AI-driven analytics and data management platforms, is optimizing vaccine distribution and monitoring, presenting lucrative opportunities for stakeholders.

Market Segmentation
TypeRecombinant Vaccines, DNA Vaccines, RNA Vaccines, Subunit Vaccines, Vector-Based Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Synthetic Vaccines
ProductVaccine Formulations, Adjuvants, Vaccine Delivery Devices, Vaccine Packaging, Vaccine Storage Solutions
TechnologyNanoparticle Technology, Virus-Like Particles, Conjugate Technology, Gene Editing, Synthetic Biology, Reverse Vaccinology
ApplicationInfectious Diseases, Cancer Vaccines, Allergy Vaccines, Autoimmune Disorders, Neurological Disorders
End UserHospitals, Clinics, Research Institutes, Biopharmaceutical Companies, Government Organizations
ComponentAntigens, Stabilizers, Preservatives, Adjuvants
DeviceNeedle-Free Injectors, Microneedle Patches, Oral Delivery Systems, Inhalation Devices
ProcessFermentation, Cell Culture, Purification, Formulation
DeploymentOn-Premise, Cloud-Based, Hybrid
SolutionsCold Chain Management, Vaccine Tracking Systems

The Next-Generation Vaccination Technologies Market is characterized by a dynamic distribution of market share, with various companies vying for dominance through strategic pricing and innovative product launches. The competitive landscape is marked by a surge in new entrants, each offering cutting-edge solutions that promise enhanced efficacy and safety. Established players are leveraging their market presence to introduce advanced vaccines, capitalizing on the growing demand for effective immunization options. This competitive drive is further fueled by the need to address emerging infectious diseases, prompting continuous innovation and adaptation. In the realm of competition benchmarking, major pharmaceutical companies are evaluated on their technological advancements and strategic collaborations. Regulatory influences play a pivotal role, with stringent guidelines in North America and Europe shaping market entry and expansion. The market is witnessing a shift towards personalized vaccination solutions, driven by advancements in genetic research and biotechnology. The integration of AI and data analytics is enhancing vaccine development processes, positioning companies at the forefront of technological innovation. This landscape presents lucrative opportunities for stakeholders willing to navigate regulatory complexities and invest in R&D.

Geographical Overview:

The Next-Generation Vaccination Technologies Market is witnessing profound growth across several key regions, each exhibiting unique dynamics. North America is at the forefront, driven by robust research and development activities and significant investments in innovative vaccine technologies. The presence of leading biotechnology firms and a strong healthcare infrastructure further propels this growth. In Europe, the market is buoyed by substantial funding for vaccine research and a focus on public health initiatives. The region's commitment to combating infectious diseases enhances its market potential. Asia Pacific is experiencing rapid expansion, fueled by increasing healthcare expenditures and government support for vaccination programs. Emerging economies like China and India are pivotal, with rising demand for advanced vaccines. Latin America and the Middle East & Africa present promising growth pockets. In Latin America, improving healthcare infrastructure and increased awareness drive market expansion. Meanwhile, the Middle East & Africa are investing in vaccination technologies to address public health challenges and bolster healthcare resilience.

Global tariffs and geopolitical tensions are intricately influencing the Next-Generation Vaccination Technologies Market. Japan and South Korea are strategically enhancing domestic R&D capabilities to mitigate reliance on foreign vaccine inputs, while China is accelerating its push for self-sufficiency amidst export controls and tariffs. Taiwan, with its robust biotech sector, remains pivotal yet vulnerable due to geopolitical frictions. The overarching market is witnessing robust growth driven by technological advancements, though supply chain disruptions and trade disputes pose challenges. By 2035, the market is expected to evolve with increased regional collaborations and innovation. Middle East conflicts exacerbate global supply chain vulnerabilities, potentially elevating energy costs and impacting production logistics, thereby necessitating strategic resilience planning across the vaccination technology landscape.

Key Trends and Drivers:

The Next-Generation Vaccination Technologies Market is experiencing robust growth driven by advancements in biotechnology and increased investment in research and development. Key trends include the development of mRNA vaccines, which have gained prominence due to their rapid development and high efficacy. The rise of personalized vaccines tailored to individual genetic profiles is also gaining traction, offering more effective immunization strategies. Another significant trend is the integration of artificial intelligence and machine learning in vaccine development, which accelerates the identification of potential vaccine candidates. Drivers include the urgent need for pandemic preparedness and the global push for more efficient and scalable vaccine production methods. The increasing prevalence of infectious diseases and the demand for innovative vaccination solutions are further propelling market growth. Opportunities abound in emerging markets where vaccination coverage is expanding, driven by government initiatives and international collaborations. Companies investing in next-generation platforms and technologies are well-positioned to capitalize on these emerging opportunities. Moreover, the focus on improving vaccine distribution and storage, particularly in remote areas, is creating avenues for growth. As the world continues to prioritize health security, the Next-Generation Vaccination Technologies Market is poised for sustained expansion.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Component
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Deployment
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Recombinant Vaccines
    • 4.1.2 DNA Vaccines
    • 4.1.3 RNA Vaccines
    • 4.1.4 Subunit Vaccines
    • 4.1.5 Vector-Based Vaccines
    • 4.1.6 Live Attenuated Vaccines
    • 4.1.7 Inactivated Vaccines
    • 4.1.8 Synthetic Vaccines
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Vaccine Formulations
    • 4.2.2 Adjuvants
    • 4.2.3 Vaccine Delivery Devices
    • 4.2.4 Vaccine Packaging
    • 4.2.5 Vaccine Storage Solutions
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Nanoparticle Technology
    • 4.3.2 Virus-Like Particles
    • 4.3.3 Conjugate Technology
    • 4.3.4 Gene Editing
    • 4.3.5 Synthetic Biology
    • 4.3.6 Reverse Vaccinology
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Infectious Diseases
    • 4.4.2 Cancer Vaccines
    • 4.4.3 Allergy Vaccines
    • 4.4.4 Autoimmune Disorders
    • 4.4.5 Neurological Disorders
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Biopharmaceutical Companies
    • 4.5.5 Government Organizations
  • 4.6 Market Size & Forecast by Component (2020-2035)
    • 4.6.1 Antigens
    • 4.6.2 Stabilizers
    • 4.6.3 Preservatives
    • 4.6.4 Adjuvants
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Needle-Free Injectors
    • 4.7.2 Microneedle Patches
    • 4.7.3 Oral Delivery Systems
    • 4.7.4 Inhalation Devices
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Fermentation
    • 4.8.2 Cell Culture
    • 4.8.3 Purification
    • 4.8.4 Formulation
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 On-Premise
    • 4.9.2 Cloud-Based
    • 4.9.3 Hybrid
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Cold Chain Management
    • 4.10.2 Vaccine Tracking Systems

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Component
      • 5.2.1.7 Device
      • 5.2.1.8 Process
      • 5.2.1.9 Deployment
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Component
      • 5.2.2.7 Device
      • 5.2.2.8 Process
      • 5.2.2.9 Deployment
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Component
      • 5.2.3.7 Device
      • 5.2.3.8 Process
      • 5.2.3.9 Deployment
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Component
      • 5.3.1.7 Device
      • 5.3.1.8 Process
      • 5.3.1.9 Deployment
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Component
      • 5.3.2.7 Device
      • 5.3.2.8 Process
      • 5.3.2.9 Deployment
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Component
      • 5.3.3.7 Device
      • 5.3.3.8 Process
      • 5.3.3.9 Deployment
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Component
      • 5.4.1.7 Device
      • 5.4.1.8 Process
      • 5.4.1.9 Deployment
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Component
      • 5.4.2.7 Device
      • 5.4.2.8 Process
      • 5.4.2.9 Deployment
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Component
      • 5.4.3.7 Device
      • 5.4.3.8 Process
      • 5.4.3.9 Deployment
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Component
      • 5.4.4.7 Device
      • 5.4.4.8 Process
      • 5.4.4.9 Deployment
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Component
      • 5.4.5.7 Device
      • 5.4.5.8 Process
      • 5.4.5.9 Deployment
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Component
      • 5.4.6.7 Device
      • 5.4.6.8 Process
      • 5.4.6.9 Deployment
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Component
      • 5.4.7.7 Device
      • 5.4.7.8 Process
      • 5.4.7.9 Deployment
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Component
      • 5.5.1.7 Device
      • 5.5.1.8 Process
      • 5.5.1.9 Deployment
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Component
      • 5.5.2.7 Device
      • 5.5.2.8 Process
      • 5.5.2.9 Deployment
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Component
      • 5.5.3.7 Device
      • 5.5.3.8 Process
      • 5.5.3.9 Deployment
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Component
      • 5.5.4.7 Device
      • 5.5.4.8 Process
      • 5.5.4.9 Deployment
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Component
      • 5.5.5.7 Device
      • 5.5.5.8 Process
      • 5.5.5.9 Deployment
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Component
      • 5.5.6.7 Device
      • 5.5.6.8 Process
      • 5.5.6.9 Deployment
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Component
      • 5.6.1.7 Device
      • 5.6.1.8 Process
      • 5.6.1.9 Deployment
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Component
      • 5.6.2.7 Device
      • 5.6.2.8 Process
      • 5.6.2.9 Deployment
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Component
      • 5.6.3.7 Device
      • 5.6.3.8 Process
      • 5.6.3.9 Deployment
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Component
      • 5.6.4.7 Device
      • 5.6.4.8 Process
      • 5.6.4.9 Deployment
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Component
      • 5.6.5.7 Device
      • 5.6.5.8 Process
      • 5.6.5.9 Deployment
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Cure Vac
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Valneva
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Novavax
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Inovio Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Vaxart
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Geo Vax Labs
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Moderna
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Bio NTech
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Dynavax Technologies
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Bavarian Nordic
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Arcturus Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Immunomic Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Medicago
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Altimmune
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Emergent Bio Solutions
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Gritstone Oncology
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Sorrento Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Translate Bio
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Vir Biotechnology
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Icosavax
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us